Erythropoietin-induced treatment costs in patients suffering from renal anemia - A comparison between biosimilar and originator drugs

Gesundheitswesen

Volumn 76, Issue 11, 2014, Pages e79-e84

  Horbrand F ^a   Rottenkolber, D ^b   Fischaleck, J ^a   Hasford, J ^b  

^a Kassenarztliche Vereinigung Bayerns   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

biosimilar drug; erythropoietin; originator drug; outpatient sector; treatment costs

Indexed keywords

BIOSIMILAR PHARMACEUTICALS; HEMATINICS;

ANEMIA; COMPARATIVE STUDY; COST-BENEFIT ANALYSIS; DRUG PRESCRIPTIONS; ECONOMICS; EPIDEMIOLOGY; GERMANY; HEALTH CARE COSTS; HEALTH EXPENDITURES; HUMANS; RENAL INSUFFICIENCY, CHRONIC; STATISTICS AND NUMERICAL DATA;

ANEMIA; BIOSIMILAR PHARMACEUTICALS; COST-BENEFIT ANALYSIS; DRUG PRESCRIPTIONS; GERMANY; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEMATINICS; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84893177614     PISSN: 09413790     EISSN: 14394421     Source Type: Journal    
DOI: 10.1055/s-0033-1361111     Document Type: Article

References (30)

1. Haustein R., de Millas C., Höer A. et al. Einsparungen für die europäischen Gesundheitssysteme durch Biosimilars. Monitor Versorgungsforschung: 2012; 5 49 54
2. European Medicines Agency Guideline on Similar Biological Medicinal Products. CHMP/437/04 Rev 1. Im Internet http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/05/WC500142978.pdf Zugriff: 22/05/2013
3. Dranitsaris G., Amir E., Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs: 2011; 71 1527 1536
4. Curran M. P., McCormack P. L. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs: 2008; 68 1139 1156
5. Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res: 2011; 3 29 36
6. Jelkmann W. Biosimilar epoetins and other follow-on biologics: update on the European experiences. Am J Hematol: 2010; 85 771 780
7. Mattison N., Mestre-Ferrandiz J., Towse A. Biosimilars: How much entry and price competition will result? London Office of Health Economics: 2010
8. Mengel K. Antianämika. In: Schwabe U., Paffrath D. Hrsg Arzneiverordnungsreport 2011. Berlin Heidelberg Springer-Verlag: 2011; 299 309
9. Drueke T. B., Locatelli F., Clyne N. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med: 2006; 355 2071 2084
10. Horl W. H., Vanrenterghem Y., Canaud B. et al. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. Nephrol Dial Transplant: 2005; 20 03 iii25 iii32
11. Singh A. K., Szczech L., Tang K. L. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med: 2006; 355 2085 2098
12. Spitzenverband Bund der Krankenkassen Rahmenvertrag über die Arzneimittelversorgung nach § 129 Absatz 2 SGB V in der Fassung vom 1. Februar 2011 (mit Anlage 1 in der Fassung vom 1. August 2011). Im Internet: http://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung-1/arzneimittel/rahmenvertraege/apotheken/20110808-S-RVtg-129-01-08-2011-17261.pdf Zugriff: 23/07/2012
13. Locatelli F., Del Vecchio L. An expert opinion on the current treatment of anemia in patients with kidney disease. Expert Opin Pharmacother: 2012; 13 495 503
14. Schellekens H. The first biosimilar epoetin: but how similar is it? Clin J Am Soc Nephrol: 2008; 3 174 178
15. o.V. Zahl der Dialysepatienten steigt. Im Internet http://www.aerzteblatt.de/nachrichten/41258/Zahl-der-Dialysepatienten-steigt.htm Zugriff: 18/05/2010
16. Ranchon F., Hedoux S., Laville M. et al. Direct medical cost of erythropoiesis-stimulating agents in anaemia treatment of chronic renal failure patient: a literature review. Nephrol Ther: 2010; 6 97 104
17. Hörbrand F., Bramlage P., Fischaleck J. et al. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6 117 patients with renal anaemia. Eur J Clin Pharmacol: 2013; 69 929 936
18. Krauth C., Hessel F., Hansmeier T. et al. Empirical standard costs for health economic evaluation in Germany - a proposal by the working group methods in health economic evaluation. Gesundheitswesen: 2005; 67 736 746
19. Windt R. Biologicals und Biosimilars. In: Glaeske G., Schicktanz C. Hrsg. BARMER GEK Arzneimittelreport 2011. Auswertungsergebnisse der BARMER GEK Arzneimitteldaten aus den Jahren 2009-2010: 2011
20. Association of Statutory Health Insurance Physicians Bavaria Arzneimittelvereinbarung 2010. Im Internet http://www.kvb.de/praxis/verordnungen/gesetzliche-grundlagen/gesetzliche-grundlagen-arzneimittel/amv-2010/ Zugriff: 02/08/2012
21. Horl W. H., Locatelli F., Haag-Weber M. et al. Prospective multicenter study of HX575 (biosimilar epoetin-alpha) in patients with chronic kidney disease applying a target hemoglobin of 10-12 g/dl. Clin Nephrol: 2012; 78 24 32
22. Grabowski H. Follow-on biologics: data exclusivity and the balance between innovation and competition. Nat Rev Drug Discov: 2008; 7 479 488
23. Agarwal N., Prchal J. T. Erythropoietic agents and the elderly. Semin Hematol: 2008; 45 267 275
24. Courtney A. E., McNamee P. T., Maxwell A. P. Cost should be the principal determinant of choice of erythropoiesis-stimulating agent in chronic haemodialysis patients. Nephron Clin Pract: 2007; 107 c14 c19
25. Lafeuille M. H., Bailey R. A., Vekeman F. et al. Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease. Consult Pharm: 2010; 25 493 500
26. Schiller B., Doss S., Cock D. E. et al. Costs of managing anemia with erythropoiesis-stimulating agents during hemodialysis: a time and motion study. Hemodial Int: 2008; 12 441 449
27. Sharma A., Yee J., Gandra S. R. et al. Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population. Curr Med Res Opin: 2010; 26 2679 2687
28. Duh M. S., Mody S. H., Scott McKenzie R. et al. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Clin Ther: 2006; 28 1443 1450
29. Aspinall S. L., Cunningham F. E., Zhao X. et al. Impact of Pharmacist-Managed Erythropoiesis-Stimulating Agents Clinics for Patients With Non-Dialysis-Dependent CKD. Am J Kidney Dis: 2012; 60 371 379
30. Ohashi N., Sakao Y., Yasuda H. et al. Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease. Int J Nephrol Renovasc Dis: 2012; 5 53 60